Personal genome diagnostics study shows limitations of tumor-only sequencing for cancer
BALTIMORE, MD, April 15, 2015 - Personal Genome Diagnostics, Inc. (PGDx), a provider of advanced cancer genome analysis and testing services, today announced the publication of a landmark study showing that many of the genetic alterations identified using tumor-only sequencing are not actually associated with the cancer, but instead reflect inherited germline mutations already present in the normal cells of the individual. The study is in the April 15 edition of Science Translational Medicine1 and was conducted by PGDx scientists working in collaboration with company co-founders ...



